NYSE:GSK

GlaxoSmithKline Stock Forecast, Price & News

$40.64
+0.40 (+0.99 %)
(As of 08/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$40.26
$40.65
50-Day Range
$38.39
$40.66
52-Week Range
$33.26
$42.40
Volume3.54 million shs
Average Volume5.19 million shs
Market Capitalization$109.43 billion
P/E Ratio17.15
Dividend Yield5.16%
Beta0.7
30 days | 90 days | 365 days | Advanced Chart
Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GlaxoSmithKline and its competitors with MarketBeat's FREE daily newsletter.


GlaxoSmithKline logo

About GlaxoSmithKline

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.11 out of 5 stars

Medical Sector

447th out of 1,309 stocks

Pharmaceutical Preparations Industry

224th out of 646 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 3.3Insider Behavior: 0.8Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

Is GlaxoSmithKline a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GlaxoSmithKline stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GlaxoSmithKline
or view top-rated stocks.

What stocks does MarketBeat like better than GlaxoSmithKline?

Wall Street analysts have given GlaxoSmithKline a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GlaxoSmithKline wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 14,450,000 shares, a decline of 22.4% from the June 15th total of 18,630,000 shares. Based on an average trading volume of 4,580,000 shares, the short-interest ratio is currently 3.2 days. Currently, 0.6% of the shares of the stock are sold short.
View GlaxoSmithKline's Short Interest
.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for GlaxoSmithKline
.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its earnings results on Tuesday, February, 2nd. The pharmaceutical company reported $0.62 EPS for the quarter, missing the Zacks' consensus estimate of $0.64 by $0.02. The pharmaceutical company had revenue of $8.74 billion for the quarter, compared to analysts' expectations of $8.71 billion. GlaxoSmithKline had a net margin of 13.40% and a trailing twelve-month return on equity of 26.21%. GlaxoSmithKline's revenue for the quarter was down 1.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.39 earnings per share.
View GlaxoSmithKline's earnings history
.

How has GlaxoSmithKline's stock been impacted by Coronavirus (COVID-19)?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GSK stock has increased by 1.9% and is now trading at $40.64.
View which stocks have been most impacted by COVID-19
.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline declared a quarterly dividend on Friday, July 30th. Stockholders of record on Friday, August 20th will be paid a dividend of $0.523 per share on Thursday, October 7th. This represents a $2.09 dividend on an annualized basis and a dividend yield of 5.15%. The ex-dividend date is Thursday, August 19th.
View GlaxoSmithKline's dividend history
.

Is GlaxoSmithKline a good dividend stock?

GlaxoSmithKline pays an annual dividend of $2.07 per share and currently has a dividend yield of 5.16%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of GlaxoSmithKline is 69.46%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 69.00% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend.
View GlaxoSmithKline's dividend history.

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:
  • Emma N. Walmsley, Chief Executive Officer & Executive Director
  • Iain James Mackay, Chief Financial Officer & Executive Director
  • Jon Ellis, VP & Head-Technology Business Development
  • Karenann K. Terrell, Chief Digital & Technology Officer
  • Hal V. Barron, Executive Director & Chief Scientific Officer

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), The Walt Disney (DIS) and NVIDIA (NVDA).

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by many different institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.65%), Douglas Lane & Associates LLC (0.06%), Kornitzer Capital Management Inc. KS (0.03%), Letko Brosseau & Associates Inc. (0.03%), Welch & Forbes LLC (0.02%) and Advisor Group Holdings Inc. (0.02%).
View institutional ownership trends for GlaxoSmithKline
.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Oppenheimer Asset Management Inc., Wealth Advisors of Tampa Bay LLC, Whittier Trust Co., Lakeview Capital Partners LLC, Hoertkorn Richard Charles, Financial Counselors Inc., and Advisors Asset Management Inc..
View insider buying and selling activity for GlaxoSmithKline
or view top insider-selling stocks.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Keating Investment Counselors Inc., Douglas Lane & Associates LLC, Arkadios Wealth Advisors, Brookstone Capital Management, Letko Brosseau & Associates Inc., Advisor Group Holdings Inc., and NEXT Financial Group Inc.
View insider buying and selling activity for GlaxoSmithKline
or or view top insider-buying stocks.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $40.64.

How much money does GlaxoSmithKline make?

GlaxoSmithKline has a market capitalization of $109.43 billion and generates $43.79 billion in revenue each year. The pharmaceutical company earns $7.38 billion in net income (profit) each year or $2.98 on an earnings per share basis.

How many employees does GlaxoSmithKline have?

GlaxoSmithKline employs 94,066 workers across the globe.

When was GlaxoSmithKline founded?

GlaxoSmithKline was founded in 2000.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

Where are GlaxoSmithKline's headquarters?

GlaxoSmithKline is headquartered at 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 442080475000 or via email at [email protected]


This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.